Pyrimidine derivatives

摘要

The invention provides novel pyrimidine derivatives of formula (I), methods of preparing such compounds, pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer; wherein R1-R11, Z, and Y are as defined in the specification.;

主权项

1. A compound of formula I or a pharmaceutically acceptable ester, solvate or salt thereof, wherein Z represents carbon or nitrogen; Y represents carbon or nitrogen, wherein one of Z and Y represents nitrogen; R1, R3, and R8 are independently selected from the group consisting of hydrogen and (C1-C4)alkyl; R2 is selected from the group consisting of hydrogen, (C1-C4)alkyl, (C1-C4)alkyl-NH(C1-C4)alkyl, (C1-C4)alkyl-N[(C1-C4)alkyl ]2, and (CO)OH; R4, R5, R6, and R7 are independently selected from the group consisting of hydrogen, halogen, hydroxy, amino, nitro, cyano, (C1-C4)alkyl, (C1-C4)alkyl-OH, (C1-C4)alkyl-NH2, (C1-C4)alkyl-NH(C1-C4)alkyl, (C1-C4)alkyl-N[(C1-C4)alkyl]2, (C1-C4)alkyl-NH(CO)(C1-C4)alkyl, (CO)OH, (CO)NH2, (CO)NH(C1-C4)alkyl, (CO)N[(C1-C4)alkyl]2, O(C1-C4)alkyl, O(C1-C4)alkyl(C2-C5)heterocyclyl, O(C1-C4)alkyl(C2-C5)heterocyclyl(C1-C4)alkyl, O(C1-C4)alkyl(CO)OH, O(C1-C4)alkyl(CO)NH(C1-C4)alkyl, O(C1-C4)alkyl(CO)N[(C1-C4)alkyl]2, OCF3, NH(C1-C4)alkyl, N[(C1-C4)alkyl ]2, NH(CO)(C1-C4)alkyl, NHSO2(C1-C4)alkyl, N[(C1-C4)alkyl]SO2(C1-C4)alkyl, SH, S(C1-C4)alkyl, SO2NH2, SO2NH(C1-C4)alkyl, and SO2N[(C1-C4)alkyl]2; each R10 is independently selected from the group consisting of hydrogen, amino, and (C1-C4)alkyl when Z or Y is carbon; R11 is selected from the group consisting of hydrogen, amino, (C1-C4)alkyl, (C1-C4)alkyl(C2-C5)heterocyclyl, (C1-C4)alkyl(C2-C5)heterocyclyl(C1-C4)alkyl, (CO)OH, (CO)NH2, (CO)NH(C1-C4)alkyl, (CO)N[(C1-C4)alkyl]2, (CO)(C1-C4)alkyl, (C2-C5)heterocyclyl, (C2-C5)heterocyclyl(C1-C4)alkyl, NH(C1-C4)alkyl, N[(C1-C4)alkyl]2, NH(CO)(C1-C4)alkyl, NHSO2(C1-C4)alkyl, N[(C1-C4)alkyl]SO2(C1-C4)alkyl, SO2NH2, SO2NH(C1-C4)alkyl, and SO2N[(C1-C4)alkyl]2; R9 represents R12, R13, and R14 are independently selected from the group consisting of hydrogen, halogen, hydroxy, (C1-C4)alkyl, O(C1-C4)alkyl, NH(C1-C4)alkyl, and N[(C1-C4)alkyl]2; R15 is selected from hydrogen and (C1-C4)alkyl; and R16 and R17 are independently selected from the group consisting of hydrogen, halogen, (C1-C4)alkyl, (C1-C4)alkyl(C2-C5)heterocyclyl, (C1-C4)alkyl(C2-C5)heterocyclyl(C1-C4)alkyl, (C1-C4)alkyl(CO)OH, (C1-C4)alkyl(CO)NH2, (C1-C4)alkyl(CO)NH(C1-C4)alkyl, (C1-C4)alkyl(CO)N[(C1-C4)alkyl]2, (C1-C4)alkyl-OH, (C1-C4)alkyl-O(C1-C4)alkyl, (C1-C4)alkyl-NH(C1-C4)alkyl, (C1-C4)alkyl-N[(C1-C4)alkyl]2, (C1-C4)alkyl-NH(CO)(C1-C4)alkyl, (CO)OH, (CO)NH2, (CO)NH(C1-C4)alkyl, (CO)N[(C1-C4)alkyl]2, (CO)(C1-C4)alkyl, (CO)(C2-C5)heterocyclyl, and (CO)(C2-C5)heterocyclyl)(C1-C4)alkyl.